Article

Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China

2020-01-21

Abstract excerpt

<title>Abstract</title> <p>Objective : The purpose of the present study was to obtain information on the use of PD-1/PD-L1 inhibitors by oncologists in China through a national questionnaire survey. Materials and Methods : Between the 7th and 25th of July in 2019, a questionnaire designed by the Chinese Society of Clinical Oncology Immuno-Oncology (CSCO IO) Committee on the current status of the use of PD-1/PD-L1...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 25eddade-3ab9-5ab3-aa5d-624cab958768
DOI: 10.21203/rs.2.16866/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in ChinaDOI 10.21203/rs.2.16866/v2Read

Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumorsSemantic proximity Read

Access to Essential and Innovative Anti-cancer Medicines: A Longitudinal Study in Nanjing, ChinaSemantic proximity Read

Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi ArabiaSemantic proximity Read

PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applicationsSemantic proximity Read

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in PolandSemantic proximity Read

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitorsSemantic proximity Read

Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)Semantic proximity Read

Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF -mutated melanoma patients in the United States.Semantic proximity Read

Non-Clinical Evaluation of the Anti-PD-1 Antibody UDIZ-007Semantic proximity Read

Nivolumab plus ipilimumab for elderly Chinese patients with advanced non-small cell lung cancerSemantic proximity Read

Enhancing First-Line TKI Efficacy in PD-L1-Positive EGFR-Mutated NSCLC: The Role of Antiangiogenic AgentsSemantic proximity Read

Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.Semantic proximity Read